Target intelligence / Profile preview

Metalloproteinase inhibitor 3 (TIMP3) mRNA (TIMP3 mRNA)

Target
TIMP3 mRNA
Molecular classification
Messenger RNA, Nucleic acid, Metalloproteinase inhibitor family
01

Overview

Metalloproteinase inhibitor 3 (TIMP3) mRNA encodes a critical regulator of the extracellular matrix (ECM) that is unique among the TIMP family for its strong affinity for the ECM [3, 4]. The TIMP3 protein functions as a potent inhibitor of a wide range of matrix metalloproteinases (MMPs), ADAMs, and ADAMTSs, thereby controlling tissue remodeling, angiogenesis, and inflammatory signaling [1, 7]. The TIMP3 mRNA itself is characterized by an unusually long 3' untranslated region (UTR), which serves as a regulatory hub for numerous microRNAs, such as miR-21 and miR-221, that frequently downregulate its expression in pathological states [3, 11]. In oncology, reduced TIMP3 mRNA levels are associated with tumor invasion, metastasis, and poor prognosis, while mutations in the TIMP3 gene are the primary cause of Sorsby fundus dystrophy, a rare degenerative retinal disease [2, 5, 9]. Therapeutic strategies targeting TIMP3 mRNA include the use of antisense oligonucleotides and siRNAs to modulate expression in research settings, as well as the potential for mRNA-based replacement therapies to restore tumor-suppressive or cardioprotective functions [14, 17, 20]. Additionally, epigenetic modulators like DNA methyltransferase inhibitors are used to indirectly upregulate TIMP3 mRNA expression by reversing promoter hypermethylation [1, 11].

Other names
Tissue inhibitor of metalloproteinases 3 mRNATIMP-3 mRNAMetalloproteinase inhibitor 3 mRNASFD mRNA
02

Mechanism of action

RNA interference, antisense inhibition, mRNA replacement, and epigenetic induction of gene expression.

03

Biological functions

Extracellular matrix remodelingProtease inhibitionAngiogenesis regulationApoptosis inductionInflammation regulation
04

Disease associations

CancerSorsby fundus dystrophyCardiovascular diseaseMacular degenerationInflammation
05

Safety considerations

Off-target effects of RNA-based therapeuticsTissue-specific delivery challengesPotential for tissue fibrosis due to excessive MMP inhibition
06

Interacting drugs

TIMP3 siRNA

5 more in the full profile.

07

Biomarkers

TIMP3 mRNA expression levelTIMP3 promoter methylation statusMMP-2 activityMMP-9 activity

Beyond the preview

Go deeper on Metalloproteinase inhibitor 3 (TIMP3) mRNA (TIMP3 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metalloproteinase inhibitor 3 (TIMP3) mRNA (TIMP3 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call